13F Holdings
中文EN

BWAY Brainsway Ltd. IFRS

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1505065

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY29.0%
TTM net income YoY169.6%
TTM EPS YoY138.5%
Revenue 3-yr CAGR11.4%
Net income 3-yr CAGR—

Margins

Gross margin74.6%
Operating margin3.4%
Net margin7.1%
FCF margin—
EBITDA margin5.0%

Returns

ROE5.6%
ROA3.7%
ROIC (approx.)9.8%
Asset turnover0.52x

Leverage & solvency

Liabilities / assets33.9%
Debt / equity0.00x
Current ratio5.19x
Interest coverage0.92x

Cash quality & payout

Operating cash flow / net income3.53x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31FY2020*2020-12-31
Income statement
Revenue$41.02M$31.79M$27.18M$29.66M$22.06M
Cost of revenue$10.44M$8.31M$7.13M$6.60M$5.06M
Gross profit$30.58M$23.48M$20.05M$23.06M$17.00M
R&D expense$7.19M$6.67M$7.68M$6.39M$5.82M
SG&A expense$5.80M$5.32M$6.85M$5.78M$4.72M
Operating income$1.39M-$4.96M-$12.68M-$5.00M-$4.83M
Interest expense$1.52M$1.16M$1.47M-$1.68M$319,000
Pretax income$3.46M-$3.95M-$13.03M-$6.42M-$5.15M
Income tax$538,000$251,000$315,000$43,000$237,000
Net income$2.92M-$4.20M-$13.35M-$6.46M-$5.38M
EBITDA$2.05M-$4.60M-$12.12M-$4.44M-$4.39M
EPS (basic)0.09-0.13-0.40-0.21-0.24
EPS (diluted)0.05-0.13-0.40-0.21-0.24
Balance sheet
Cash & equivalents$69.34M$10.52M$47.58M$16.92M$16.96M
Receivables$4.60M$3.78M$4.84M$6.33M$5.58M
Inventory$4.43M$3.72M$3.84M——
Current assets$79.67M$55.47M$58.09M$65.45M$24.30M
PP&E, netmay include right-of-use assets (IFRS)————$4.35M
Total assets$94.32M$62.97M$64.48M$75.73M$34.01M
Current liabilities$15.35M$9.76M$8.14M$9.07M$6.80M
Total liabilities$32.00M$21.39M$19.08M$18.41M$14.38M
Shareholders' equity$62.31M$41.58M$45.40M$57.33M$19.63M
Shares outstanding37.63M33.24M33.05M32.91M22.25M
Cash flow statement
Operating cash flow$10.30M$1.28M-$9.76M$884,000-$1.44M
Capital expenditure———$2.24M$2.47M
Free cash flow———-$1.35M-$3.91M
Investing cash flow$30.31M-$37.41M$42.17M-$42.22M-$2.46M
Financing cash flow$18.26M-$1.03M-$1.55M$41.52M-$1.03M
Depreciation & amortization$660,000$362,000$558,000$560,000$438,000
Stock-based compensation$1.44M$381,000$1.47M$1.89M$799,000

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.